Cargando…

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials

A meta-analysis of randomized clinical trials (RCT) was done to determine the relative risk (RR) of acute kidney injury (AKI) with the use of mammalian target of rapamycin (mTOR) inhibitors. Citations from PubMed/Medline, clinical trials.gov, package inserts and abstracts from major conferences were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paluri, Ravi K., Sonpavde, Guru, Morgan, Charity, Rojymon, Jacob, Mar, Anastasia Hartzes, Gangaraju, Radhika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886005/ https://www.ncbi.nlm.nih.gov/pubmed/31857859 http://dx.doi.org/10.4081/oncol.2019.455

Ejemplares similares

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Advances in pancreatic cancer biomarkers
por: Hasan, Syed, et al.
Publicado: (2019)

Therapeutic options for ampullary carcinomas. A review
por: Regalla, Dileep Kumar Reddy, et al.
Publicado: (2019)

The Clinical Benefit of Adjuvant Therapy in Long-Term Survival of Early-Stage Ampullary Carcinoma: A Single Institutional Experience
por: Manne, Ashish, et al.
Publicado: (2020)

Role of chemoradiation in gallbladder cancer—a single institution retrospective analysis
por: Paluri, Ravi Kumar, et al.
Publicado: (2023)

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma
por: Kornakiewicz, Anna, et al.
Publicado: (2013)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08
por: Kim, Ki Hyang, et al.
Publicado: (2016)

New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy
por: Helmschrott, Matthias, et al.
Publicado: (2017)

SUN-332 Autoimmune Endocrinopathies Associated with CTLA-4 Inhibitors: A Meta-Analysis
por: Darapu, Hima, et al.
Publicado: (2019)

Wound complications frequency in heart transplant recipients on mammalian target of rapamycin inhibitors: A meta‐analysis
por: Zhu, Shenyu, et al.
Publicado: (2023)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Prognostic markers in renal cell carcinoma: A focus on the ‘mammalian target of rapamycin’ pathway
por: Youssef, Ramy F., et al.
Publicado: (2012)

Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions
por: Tanrısev, Mehmet, et al.
Publicado: (2021)

Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant
por: Kumar, Jayant, et al.
Publicado: (2017)

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
por: Groenewoud, Marlous J., et al.
Publicado: (2013)

Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers
por: Cheung, Chi Yuen, et al.
Publicado: (2017)

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
por: Hasbal, Nuri Baris, et al.
Publicado: (2021)

Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?
por: Trimarchi, Hernán, et al.
Publicado: (2012)

Mammalian Target of Rapamycin Regulates Nox4-Mediated Podocyte Depletion in Diabetic Renal Injury
por: Eid, Assaad A., et al.
Publicado: (2013)

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma
por: NUMAKURA, KAZUYUKI, et al.
Publicado: (2014)

Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies
por: Navarro-Villarán, Elena, et al.
Publicado: (2016)

Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors
por: Tamada, Satoshi, et al.
Publicado: (2018)

Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
por: ZHANG, DEJUN, et al.
Publicado: (2014)

SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
por: Ghosh, Hiyaa Singhee, et al.
Publicado: (2010)

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Driving neural regeneration through the mammalian target of rapamycin
por: Maiese, Kenneth
Publicado: (2014)

Autism Spectrum Disorder and Mammalian Target of Rapamycin System
por: Posar, Annio, et al.
Publicado: (2020)

Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
por: Yan, Junfang, et al.
Publicado: (2021)

Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zeng, Jun, et al.
Publicado: (2021)

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
por: Kuroshima, Kazuki, et al.
Publicado: (2020)

Decreased Expression of Urinary Mammalian Target of Rapamycin mRNA Is Related to Chronic Renal Fibrosis in IgAN
por: Cao, Yuhan, et al.
Publicado: (2019)

Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin-mediated autophagy
por: Lin, Fan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tckb8e99k3m71fd924aogj640g